Namwiwat Medical Corporation, or NAM, has announced a five-pillar growth strategy to expand from a developer and distributor of medical device products into a broader provider of healthcare innovations and solutions. Chief Executive Officer Wirot Chaitherdkiat said the five engines are expanding the product portfolio from upstream to downstream, brand building, overseas market expansion, the use of strategic partnerships, and efficient cost management, alongside continuous development of medical innovations. On overseas markets, NAM is expanding its footprint through subsidiaries in Malaysia and Italy, as well as setting up an SKD parts assembly base in Indonesia with a local partner. Revenue from overseas currently accounts for about 5% and the company expects it to rise significantly over the next three years. For its business targets, NAM aims for 2026 revenue of 2.4 billion baht, growing 10–12% from the previous year, while pressing ahead with its Jump+ plan, with a net profit target of 380 million baht in 2028.
Namwiwat MedicalNAM announced a five-pillar growth strategy including overseas market expansion via subsidiaries in Malaysia and Italy and an SKD assembly base in Indonesia, targeting 2.4 billion baht 2026 revenue and 380 million baht net profit by 2028.
